Xconomy: Many Biotechs Need Inside IPO Help, But Selecta Is An Extreme Case

Back Bay’s Managing Partner and CEO, Jonathan Gertler, was quoted in Xconomy’s article on the public investors attitude toward biotech IPOs this year, where insiders have had to step up to help their companies go public.

“It’s hard to draw conclusions about any particular biotech that leans on its friends come IPO time. Sometimes investors may just want to double down on a company they believe in. 

“I view this as a responsible action,” says Jonathan Gertler, the CEO of life sciences consulting firm Back Bay Life Science Advisors.

“It’s a vote of confidence in the company so that you’re not just perceived as transferring risk to a public investor, but willing to put your money where your mouth is.”

Read more at Xconomy